Drug Profile
Research programme: radiation protection therapeutics - Proteome Systems
Latest Information Update: 16 Jan 2009
Price :
$50
*
At a glance
- Originator Proteome Systems
- Developer Tyrian Diagnostics
- Class Small molecules
- Mechanism of Action Free radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Radiation injuries
Most Recent Events
- 25 Oct 2005 Preclinical trials in Radiation injuries in USA (unspecified route)